摘要
目的探讨卡维地洛治疗慢性充血性心力衰竭的临床疗效及安全性。方法将2014年2月至2015年2月收治的84例慢性充血性心力衰竭患者,根据随机数字表法分为对照组(美托洛尔)和观察组(卡维地洛)。结果与对照组相比,观察组总有效率明显升高(P<0.05);治疗后心率(HR)、血压(BP)、左心室舒张末期内径(LVEDD)水平明显降低,左心室射血分数(LVEF)水平明显升高(P<0.05);不良反应发生率显著降低(P<0.05)。结论卡维地洛能明显改善慢性充血性心力衰竭患者的心功能,发挥较显著的临床疗效及有较高的安全性,值得临床推广。
Objective To study the clinical efficacy and safety of carvedilo in treating chronic congestive heart failure. Methods 84 patients with chronic congestive heart failure in the hospital during the period from February 2014 to February 2015 were divided into the control group( metoprolol) and the observation group( carvedilo) according to the random number method. Results Compared with the control group, the total effective rate was significantly increased in the observation group( P < 0. 05); the level of HR, BP and LVEDD were significantly reduced and the level of LVEF was obviously increased in the observation group( P < 0. 05); the incidence rate of adverse reactions was significantly decreased( P < 0. 05). Conclusion Carvedilo can significantly improve the heart function for patients with chronic congestive heart failure,play the more significant efficacy and higher safety,and is worthy of clinical promotion.
出处
《中国药业》
CAS
2015年第21期188-189,共2页
China Pharmaceuticals
